
Vigeo Therapeutics, a clinical-stage biopharmaceutical firm, pioneers novel cancer treatments and drug discovery, founded in 2011.
Vigeo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic agents to treat advanced malignant tumors and improve patient outcomes. Founded in 2011, the company is building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to conduct multiple combination studies to evaluate VT1021 with chemotherapies and anti-PD-1 antibodies.
Vigeo Therapeutics has made significant strides in cancer treatment innovation, particularly with their lead candidate, VT1021. Their approach aims to enhance the effectiveness of existing cancer therapies, potentially transforming the standard of care for various cancer types. The company's pioneering work in TIME reprogramming positions them as a notable player in the biopharmaceutical industry.

Veana Therapeutics
Virsti Therapeutics

Eugit Therapeutics

Tango Therapeutics
tangotx.com

Palm Therapeutics

Parthenon Therapeutics
parthenontx.com

Vicus Therapeutics

Verseau Therapeutics
verseautx.com

Window Therapeutics
windowtx.com

Vivacitas Oncology
vivaoncology.com

Vita Therapeutics

G1 Therapeutics
g1therapeutics.com

Checkpoint Therapeutics
checkpointtx.com

Neoantigenics

Signet Therapeutics
Companies similar to Vigeo Therapeutics include Veana Therapeutics, Virsti Therapeutics, Eugit Therapeutics and Tango Therapeutics.
Vigeo Therapeutics was founded in 2011.
Vigeo Therapeutics' headquarters is located in Cambridge, MA, US.
Vigeo Therapeutics' most recent funding round was for $7.5M (USD) in March 2021.
As of Mar 25, 2021, Vigeo Therapeutics has raised a total of $10M (USD).
Vigeo Therapeutics has 16 employees as of Feb 5, 2024.